文献速递妇产影像儿科影像技术与安全US

早孕期联合筛查与侵入性诊断对非典型染色体异常的产前特征及检出率:丹麦全国研究及与无创产前检测的比较

Combined first-trimester screening and invasive diagnostics for atypical chromosomal aberrations: Danish nationwide study of prenatal profiles and detection compared with NIPT.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-09-04

该回顾性研究分析丹麦2008至2018年565708例早孕期联合筛查孕妇,发现联合筛查对常见三体检出率87%,对三倍体86%、X单体92%、非典型性染色体异常58%、罕见常染色体三体或嵌合体70%;致病性拷贝数变异占全部染色体异常的27%,仅23%联合筛查高风险,51%产后才诊断;用无创产前检测替代高风险孕妇的侵入性检测会漏诊27%的致病性异常。

要点

  • 联合筛查对常见三体、三倍体、X单体、非典型性染色体异常及罕见常染色体三体的检出率分别为87%、86%、92%、58%、70%。
  • 致病性拷贝数变异占全部染色体异常的27%,仅23%联合筛查高风险,51%产后才诊断。
  • 联合筛查高风险孕妇中,传统无创产前检测会漏诊27%的致病性异常,每26例高风险孕妇中1例异常但无创结果正常。

核心结论

  • 联合筛查作为21、18、13三体筛查的副产品,可在产前检出大多数三倍体、多数非典型性染色体异常、罕见常染色体三体及嵌合体;但仅23%的致病性拷贝数变异联合筛查高风险,仅一半产前诊断;用无创产前检测替代高风险孕妇的侵入性检测会大幅降低早孕期致病性染色体异常的检出。

研究设计与样本

  • 丹麦胎儿医学数据库回顾性综述,纳入2008年1月1日至2018年12月31日接受早孕期联合筛查并做21三体风险评分的全部孕妇565708例,染色体异常分为三倍体、常见三体、X单体、其他性染色体异常、致病性拷贝数变异、罕见常染色体三体或嵌合体六类,致病性拷贝数变异经染色体微阵列分析诊断并计算大小。

关键影像表现/征象

  • 致病性拷贝数变异妊娠与未受累妊娠相比,颈项透明层厚度显著增加,母体血清标记物妊娠相关血浆蛋白A和β-人绒毛膜促性腺激素水平显著降低。
  • 联合筛查对常见三体检出率87%、三倍体86%、X单体92%、非典型性染色体异常58%、罕见常染色体三体或嵌合体70%。
  • 致病性拷贝数变异占全部染色体异常的27%(n=1091),研究期间随产前染色体微阵列分析增加而患病率上升。
  • 孕妇年龄小于30岁、颈项透明层厚度不超过第95百分位、妊娠相关血浆蛋白A不低于1倍中位数或21三体风险不高于1/1000时,致病性拷贝数变异患病率显著超过21、18、13三体患病率。
  • 联合筛查高风险孕妇中致病性拷贝数变异占诊断异常的14%,仅23%致病性拷贝数变异妊娠联合筛查高风险,51%致病性拷贝数变异产后才诊断。

诊断标准与关键数值

  • 联合筛查对常见三体检出率87%,三倍体86%,X单体92%,非典型性染色体异常58%,罕见常染色体三体或嵌合体70%。
  • 联合筛查高风险孕妇中,传统无创产前检测(筛查21、18、13三体及X单体)会漏诊27%的侵入性检测诊断的致病性异常,每26例高风险孕妇中1例有染色体异常但传统无创产前检测结果正常。
  • 在针对中间风险组(21三体风险1/100至1/299)使用无创产前检测的 contingent 筛查模型中,50%的异常会被漏诊。
  • 79%的致病性拷贝数变异小于5Mb,现有全基因组无创产前检测无法检出。

临床应用与阅片要点

  • 联合筛查高风险孕妇中,传统无创产前检测会漏诊27%的致病性异常,每26例高风险孕妇中1例异常但无创结果正常。
  • 针对中间风险组(21三体风险1/100至1/299)使用无创产前检测的 contingent 筛查模型会漏诊50%的异常。
  • 79%的致病性拷贝数变异小于5Mb,现有全基因组无创产前检测无法检出。

局限性

  • 本文为回顾性综述。
  • 研究期间产前染色体微阵列分析使用增加,致病性拷贝数变异患病率随之上升。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Our aim was to examine the prenatal profiles of pregnancies affected by an atypical chromosomal aberration, focusing on pathogenic copy-number variants (pCNVs). We also wanted to quantify the performance of combined first-trimester screening (cFTS) and a second-trimester anomaly scan in detecting these aberrations. Finally, we aimed to estimate the consequences of a policy of using non-invasive prenatal testing (NIPT) rather than invasive testing with chromosomal microarray analysis (CMA) to manage pregnancies identified as high risk by cFTS.

METHODS: This was a retrospective review of the Danish Fetal Medicine Database of all pregnant women who underwent cFTS and a risk assessment for trisomy 21 between 1 January 2008 and 31 December 2018. Chromosomal aberrations diagnosed prenatally, postnatally or from fetal tissue following pregnancy loss or termination of pregnancy were identified. Chromosomal aberrations were grouped into one of six categories: triploidy; common trisomy (13, 18 or 21); monosomy X; other sex-chromosome aberration (SCA); pCNV; and rare autosomal trisomy (RAT) or mosaicism. The prevalence of each aberration category was stratified by the individual cFTS markers and trisomy 21 risk estimate, and the size of each pCNV diagnosed by CMA was calculated.

RESULTS: We retrieved data on 565 708 pregnancies, of which 3982 (0.70%) were diagnosed with a fetal chromosomal aberration. cFTS identified 87% of the common trisomies, but it also performed well in identifying triploidies (86%), monosomy X (92%), atypical SCAs (58%) and RATs or mosaicisms (70%). pCNVs comprised 27% (n = 1091) of the chromosomal aberrations diagnosed overall, and the prevalence increased during the study period, as prenatal CMA was increasingly being performed. In pregnancies with a maternal age < 30 years, nuchal translucency (NT) thickness ≤ 95th centile, pregnancy-associated plasma protein-A (PAPP-A) ≥ 1 multiple of the median, or trisomy 21 risk of ≤ 1 in 1000, the prevalence of pCNVs exceeded significantly the prevalence of trisomies 21, 18 and 13. Pregnancies affected by a pCNV had significantly increased NT and decreased levels of the maternal biomarkers PAPP-A and β-human chorionic gonadotropin compared with unaffected pregnancies. However, only 23% of these pregnancies screened positive on cFTS and 51% of pCNVs were not detected until after birth. Among high-risk pregnancies, pCNVs comprised 14% of diagnosed aberrations, and when other atypical aberrations were considered, conventional NIPT (screening for trisomies 21, 18 and 13 and monosomy X) would miss 27% of all pathogenic aberrations diagnosed from invasive testing following a high-risk cFTS result. Thus, 1 in 26 pregnancies at high risk following cFTS would be affected by a chromosomal aberration despite a normal result from conventional NIPT. In a contingent screening model using NIPT for the 'intermediate'-risk group (trisomy 21 risk of 1 in 100-299), 50% of the aberrations would be missed. In our cohort, 79% of the pCNVs diagnosed were < 5Mb and therefore not detectable using current forms of 'genome-wide' NIPT.

CONCLUSIONS: As a by-product of screening for trisomies 21, 18 and 13, most triploidies and the majority of atypical SCAs, RATs and mosaicisms are detected before birth. However, only 23% of pCNVs are associated with a high-risk result according to cFTS and only half are diagnosed before birth. Replacing invasive testing with NIPT for high-risk pregnancies would substantially decrease the first-trimester detection of pathogenic chromosomal anomalies. © 2024 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gadsbøll K, Vogel I, Kristensen SE, et al. Combined first-trimester screening and invasive diagnostics for atypical chromosomal aberrations: Danish nationwide study of prenatal profiles and detection compared with NIPT. Ultrasound Obstet Gynecol. 2024. PMID: 38642365. doi:10.1002/uog.27667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。